Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Layese

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.
The European Respiratory Journal|January 20, 2023
Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre studyFrédéric Schlemmer, Simon Valentin, Laurent Boyer, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.
The European Respiratory Journal|January 20, 2023
Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre studyFrédéric Schlemmer, Simon Valentin, Laurent Boyer, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
Pageof 6